PMID- 29599805
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2018
DP  - 2018
TI  - Qi-Dong-Huo-Xue-Yin Inhibits Inflammation in Acute Lung Injury in Mice via 
      Toll-Like Receptor 4/Caveolin-1 Signaling.
PG  - 2373609
LID - 10.1155/2018/2373609 [doi]
LID - 2373609
AB  - Acute lung injury (ALI) is a critical illness with no current effective 
      treatment. Caveolin-1 indirectly activates inflammation-associated signaling 
      pathways by inhibiting endothelial nitric oxide synthase (eNOS). This induces an 
      imbalance between pro- and anti-inflammatory cytokine levels, which are involved 
      in the pathogenesis of ALI. The compound Chinese prescription Qi-Dong-Huo-Xue-Yin 
      (QDHXY) is efficacious for ALI treatment via an anti-inflammatory effect; 
      however, the exact underlying mechanism is unknown. Therefore, we explored the 
      protective effect of QDHXY against lipopolysaccharide- (LPS-) induced ALI in 
      mice. Histopathological changes in mouse lung tissues were studied. Furthermore, 
      alterations in the serum levels of pro- and anti-inflammatory cytokines were 
      investigated. The levels of tumor necrosis factor- (TNF-)alpha, interleukin- (IL-) 6, 
      IL-1beta, and interferon-gamma-induced protein 10 in bronchoalveolar lavage fluid were 
      measured. Additionally, the expression levels of myeloid differentiation factor 
      88 (MyD88), caveolin-1, and eNOS were assessed. QDHXY significantly reduced lung 
      infiltration with inflammatory cells and the production of serum pro- and 
      anti-inflammatory cytokines and inhibited the expression of TNF-alpha, IL-1beta, 
      caveolin-1, and MyD88 but not eNOS. These indicate that QDHXY significantly 
      improved the balance between pro- and anti-inflammatory cytokine levels, possibly 
      by inhibiting the caveolin-1 signaling pathway. Therefore, QDHXY may be a 
      potential treatment for ALI.
FAU - Xu, Li-Ying
AU  - Xu LY
AUID- ORCID: 0000-0001-8238-106X
AD  - Department of Emergency, The First Affiliated Hospital of Zhejiang Chinese 
      Medical University, Hangzhou, China.
FAU - Cai, Wan-Ru
AU  - Cai WR
AUID- ORCID: 0000-0002-8810-1548
AD  - Department of Respiratory Medicine, The Second Affiliated Hospital of Zhejiang 
      Chinese Medical University, Hangzhou, China.
FAU - Ma, Chun-Fang
AU  - Ma CF
AD  - Department of Laboratory Medicine, The Second Affiliated Hospital of Zhejiang 
      Chinese Medical University, Hangzhou, China.
FAU - Shou, Qi-Yang
AU  - Shou QY
AUID- ORCID: 0000-0003-1615-5309
AD  - Animal Experimental Center, Zhejiang Chinese Medical University, Hangzhou, China.
FAU - Qian, Jing-Li
AU  - Qian JL
AD  - Department of Respiratory Medicine, The Second Affiliated Hospital of Zhejiang 
      Chinese Medical University, Hangzhou, China.
FAU - Huseyin, Turan S
AU  - Huseyin TS
AD  - Accident and Emergency Department, Royal Free London NHS Foundation Trust, 
      London, UK.
LA  - eng
PT  - Journal Article
DEP - 20180211
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC5827893
EDAT- 2018/03/31 06:00
MHDA- 2018/03/31 06:01
PMCR- 2018/02/11
CRDT- 2018/03/31 06:00
PHST- 2017/11/06 00:00 [received]
PHST- 2018/01/14 00:00 [accepted]
PHST- 2018/03/31 06:00 [entrez]
PHST- 2018/03/31 06:00 [pubmed]
PHST- 2018/03/31 06:01 [medline]
PHST- 2018/02/11 00:00 [pmc-release]
AID - 10.1155/2018/2373609 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2018 Feb 11;2018:2373609. doi: 
      10.1155/2018/2373609. eCollection 2018.